Venmax Drugs

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE154G01022
  • NSEID:
  • BSEID: 531015
INR
12.20
-0.03 (-0.25%)
BSENSE

Nov 20

BSE+NSE Vol: 929

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Colinz Labs
Zenith Health
Centuple Global
Ishita Drugs
Venmax Drugs
Lasa Supergeneri
Shree Ganesh Bio
Welcure Drugs
Goldline Pharmac
Bacil Pharma
Mono Pharmacare
Why is Venmax Drugs & Pharmaceuticals Ltd ?
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 0.33%
  • Poor long term growth as Net Sales has grown by an annual rate of 200.30% and Operating profit at 10.45% over the last 5 years
  • High Debt Company with a Debt to Equity ratio (avg) at 0.81 times
2
With ROE of 2, it has a Expensive valuation with a 0.9 Price to Book Value
  • ; the PEG ratio of the company is 0.1
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Icon
No Data Found
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
200.30%
EBIT Growth (5y)
10.45%
EBIT to Interest (avg)
-0.29
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.03
Sales to Capital Employed (avg)
0.32
Tax Ratio
19.57%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
-8.10%
ROE (avg)
1.20%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
46
Industry P/E
40
Price to Book Value
0.94
EV to EBIT
17.14
EV to EBITDA
17.14
EV to Capital Employed
0.94
EV to Sales
1.29
PEG Ratio
0.05
Dividend Yield
NA
ROCE (Latest)
1.65%
ROE (Latest)
2.03%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company
NET SALES(Latest six months)

At Rs 7.76 cr has Grown at 206.72%

PBDIT(Q)

Highest at Rs 0.20 cr.

PBT LESS OI(Q)

Highest at Rs 0.20 cr.

PAT(Q)

Highest at Rs 0.12 cr.

-1What is not working for the Company
CASH AND CASH EQUIVALENTS(HY)

Lowest at Rs 0.53 cr

Loading Valuation Snapshot...
Here's what is working for Venmax Drugs
Net Sales - Latest six months
At Rs 7.76 cr has Grown at 206.72%
Year on Year (YoY)
MOJO Watch
Sales trend is very positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 0.20 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 0.20 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 0.12 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Here's what is not working for Venmax Drugs
Cash and Cash Equivalents - Half Yearly
Lowest at Rs 0.53 cr
in the last six half yearly periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents